



**SUGGESTED FORMULA**

---

Dehydroepiandrosterone (DHEA) 10mg Slow Release Capsule Size #1

Version number: 1.0

Volume or quantity: 100 capsules

---

Dehydroepiandrosterone, Micronized (D1225)	1gm
Microcrystalline Cellulose, NF (C1679)	13.5gm
Hydroxypropyl Methylcellulose, USP (ME137)	10gm
Size #1 Capsules	#100

---

\*One hundred #1 capsules are required for this preparation. It is necessary to determine the quantity of cellulose diluent or other diluent required as a filler prior to beginning the preparation of this formula.

**SUGGESTED COMPOUNDING PROCEDURES**

Weigh all ingredients

1. Calculate the quantity of each ingredient for the amount to be prepared
2. Accurately weigh or measure each ingredient
3. If necessary, reduce the particle size of the DHEA to a fine powder
4. Blend the DHEA powder with the microcrystalline Cellulose geometrically
5. Add the Hydroxypropyl methylcellulose to the DHEA powder mixture geometrically until well mixed
6. Encapsulate into 100 size #1 capsules
7. Weigh sample capsules to check variability and standard deviation per pharmacy SOPs
8. Bottle and label with prescription label and appropriate auxiliary labels.
9. Suggested Quality assessments
  - a. % variability & % deviation from theoretical <10% - (remake if >10%)
  - b. Capsule size
  - c. Capsule color
  - d. Quantity
  - e. Label - auxiliary labels, storage, BUD, compounded medication

Store in air-tight container, at Controlled room temperature

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products,

organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be used based on the Current USP<795> Standards

**General:** Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

**Precautions**

Hazardous drugs should be handled according to USP and NIOSH standards and pharmacy SOPs. This preparation should be compounded in a vertical airflow hood, in a biological safety cabinet or barrier isolation technology. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

6/18 JD